Insider Cluster (3 insiders) ·Filed Jun 2, 2026

NBIX

NEUROCRINE BIOSCIENCES INC
NEUTRAL
Impact 3/10
Horizondays Processed4mo ago
Insider cluster: 3 insiders, $2.7M total
Actionable Insight • Neutral

Insider sales are routine and immaterial relative to market cap. No bearish signal. Monitor next earnings (likely late July) for any guidance changes, but this cluster does not indicate informed selling.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
NBIX ▼ -5.36% at T+60d
NEUTRAL call ✗ call lost -5.36% · α vs SPY -7.59% · entry $164.23 → $155.43
Entry anchored
Jun 2, 2026
via day open
T+1d
+1.58%
call +1.58% · α +1.18%
$166.83
settled 4mo ago
T+5d
-2.05%
call -2.05% · α +1.77%
$160.86
settled 4mo ago
T+20d
+2.16%
call +2.16% · α +3.28%
$167.77
settled 3mo ago
T+60d
-5.36%
call -5.36% · α -7.59%
$155.43
settled 5w ago

Price Chart

Loading chart...

Executive Summary

Three Neurocrine executives (CSO, Chief Corp. Affairs Officer, Chief Regulatory Officer) sold a total of $2.73M in open-market shares over a 5-day window. The sales are tied to option exercises and are small relative to the $16.2B market cap (~0.017%), making them routine portfolio diversification rather than a bearish signal. Director grants on May 27 are non-cash and carry no economic signal.

Key Financial Metrics

Direction
selling
Total Value
$2.7M
Insiders
3

Key Facts

  • Total open-market sales: $2.73M across 3 insiders (CSO, Chief Corp. Affairs Officer, Chief Regulatory Officer)
  • Sales represent ~0.017% of NBIX's $16.2B market cap — well below the 0.1% materiality threshold
  • CSO Onyia Jude sold 22,000 shares for $3.47M total across two days, all tied to option exercises at $84.74/share
  • Chief Regulatory Officer Delaet Ingrid sold 2,261 shares for $354K, also tied to option exercises
  • Seven directors received non-cash stock grants on May 27 — no economic signal
  • No 10b5-1 plan disclosure in the filing, but the pattern (option exercise + immediate sale) is standard for tax coverage

Financial Impact

Total insider sales of $2.73M, or 0.017% of market cap — immaterial

insider_sales

Risk Factors

  • No material risk identified from this insider activity alone

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
86% bullish (36 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-NBIX-1780438125207
17 reports for NBIX
Performance horizon
100% Hit rate 3 of 3 directional calls best @ T+60▲ +27.40%Apr 6, 2026
Filters
Rows
Reports for NBIX — sortable, filterable
TypeNow
Sep 15, 2026
16d ago
Insider Cluster
NEUTRAL ★ 3/10
$149.50 $139.49▼ −6.70%▼ −9.26%$142.85 (−4.45%)
Jul 13, 2026
11w ago
Insider Cluster
NEUTRAL ★ 3/10
$174.10 $170.88▼ −1.85%▼ −1.06%$142.85 (−17.95%)
Jul 9, 2026
12w ago
Press Release
NEUTRAL ★ 2/10
$177.11 $171.55▼ −3.14%▼ −2.58%$142.85 (−19.34%)
Jun 9, 2026
16w ago
Insider Cluster
NEUTRAL ★ 3/10
$160.86 $156.42▼ −2.76%▼ −6.19%$142.85 (−11.20%)
Jun 8, 2026
16w ago
Insider Cluster
NEUTRAL ★ 2/10
$165.24 $159.51▼ −3.47%▼ −5.88%$142.85 (−13.55%)
Jun 8, 2026
16w ago
Insider Cluster
NEUTRAL ★ 4/10
$165.24 $159.51▼ −3.47%▼ −5.88%$142.85 (−13.55%)
Jun 4, 2026
17w ago
Insider Cluster
NEUTRAL ★ 3/10
$163.88 $159.76▼ −2.51%▼ −3.08%$142.85 (−12.83%)
Jun 2, 2026
17w ago
Insider Cluster
NEUTRAL ★ 2/10
$164.23 $160.86▼ −2.05%▲ +1.77%$142.85 (−13.02%)
Jun 2, 2026
17w ago
Insider Cluster
NEUTRAL ★ 3/10
$164.23 $160.86▼ −2.05%▲ +1.77%$142.85 (−13.02%)
Jun 2, 2026
17w ago
Insider Cluster
NEUTRAL ★ 2/10
$164.23 $160.86▼ −2.05%▲ +1.77%$142.85 (−13.02%)
Showing 10 of 17

US Market Status

Market Open — Closes in 22m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Jun 2, 2026